Immunotherapy before surgery for stomach cancer with high microsatellite instability
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can help shrink stomach cancer and reduce the chance of it coming back. It is for people whose tumors have a specific genetic feature called MSI-H or dMMR, which often responds well to immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stomach (gastric) cancer that is stage II or III and can be removed with surgery.
- Your tumor has been tested and found to have high microsatellite instability (MSI-H) or a deficiency in mismatch repair (dMMR).
- You have not had any prior chemotherapy, radiation, or other treatment for this cancer.
- You are generally in good health, with a performance status of 0 or 1, meaning you can carry out daily activities.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether giving the immunotherapy drug sintilimab along with low-dose radiation before surgery can help shrink stomach cancer that has a specific DNA repair defect (dMMR/MSI-H). The goal is to make surgery more effective and improve outcomes.
This trial tests a combination of four drugs given before surgery for stomach cancer that can be removed but is considered borderline resectable. The goal is to shrink the tumor to make surgery more successful and potentially improve outcomes.
This trial tests a new immunotherapy drug (benmelstobart) given before and after surgery for stomach or gastroesophageal junction cancer. The goal is to see if adding this drug to standard care helps reduce the chance of the cancer coming back.
This trial tests a combination of three drugs (envollizumab, fruquintinib, and chemotherapy) given before surgery, to see if it can shrink stomach cancer enough to make it removable. It compares this combination to chemotherapy alone.
This trial tests a combination of immunotherapy (QL1706) and chemotherapy before surgery for people with early-stage stomach cancer. The goal is to see if this approach shrinks the tumor and improves surgical outcomes.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.